Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

398 ARTÍCULOS , VIENDO DEL 316 AL 330

Extracellular Vesicle Biomarkers Track Cognitive Changes Following Intranasal Insulin in Alzheimer's Disease

Mustapic M, Tran J, Craft S, Kapogiannis D.

J Alzheimers Dis. 2019;69(2):489-498. doi: 10.3233/JAD-180578.

Nanowired delivery of cerebrolysin with neprilysin and p-Tau antibodies induces superior neuroprotection in Alzheimer's disease

Sharma HS, Muresanu DF, Castellani RJ, Nozari A, Lafuente JV, Tian ZR, Ozkizilcik A, Manzhulo I, Mössler H, Sharma A.

Prog Brain Res. 2019;245:145-200. doi: 10.1016/bs.pbr.2019.03.009. Epub 2019 Apr 2.

Plasmalogens and Alzheimer's disease: a review

Su XQ, Wang J, Sinclair AJ.

Lipids Health Dis. 2019 Apr 16;18(1):100. doi: 10.1186/s12944-019-1044-1.

Advancing Alzheimer's Disease Treatment: Lessons from CTAD 2018

Vellas B, Bain LJ, Touchon J, Aisen PS.

J Prev Alzheimers Dis. 2019;6(3):198-203. doi: 10.14283/jpad.2019.11.

Target engagement in an alzheimer trial: Crenezumab lowers amyloid β oligomers in cerebrospinal fluid

Yang T, Dang Y, Ostaszewski B, Mengel D, Steffen V, Rabe C, Bittner T, Walsh DM, Selkoe DJ.

Ann Neurol. 2019 Aug;86(2):215-224. doi: 10.1002/ana.25513. Epub 2019 Jun 22.

MIND food and speed of processing training in older adults with low education, the MINDSpeed Alzheimer's disease prevention pilot trial

Clark DO, Xu H, Moser L, Adeoye P, Lin AW, Tangney CC, Risacher SL, Saykin AJ, Considine RV, Unverzagt FW.

Contemp Clin Trials. 2019 Sep;84:105814. doi: 10.1016/j.cct.2019.105814. Epub 2019 Jul 18.

The "rights" of precision drug development for Alzheimer's disease

Cummings J, Feldman HH, Scheltens P.

Alzheimers Res Ther. 2019 Aug 31;11(1):76. doi: 10.1186/s13195-019-0529-5.

Developing Effective Alzheimer's Disease Therapies: Clinical Experience and Future Directions

Elmaleh DR, Farlow MR, Conti PS, Tompkins RG, Kundakovic L, Tanzi RE.

J Alzheimers Dis. 2019;71(3):715-732. doi: 10.3233/JAD-190507.

A Pilot Study of Exenatide Actions in Alzheimer's Disease

Mullins RJ, Mustapic M, Chia CW, Carlson O, Gulyani S, Tran J, Li Y, Mattson MP, Resnick S, Egan JM, Greig NH, Kapogiannis D.

Curr Alzheimer Res. 2019;16(8):741-752. doi: 10.2174/1567205016666190913155950.

Macroalgae as a Valuable Source of Naturally Occurring Bioactive Compounds for the Treatment of Alzheimer's Disease

Olasehinde TA, Olaniran AO, Okoh AI.

Mar Drugs. 2019 Oct 25;17(11):609. doi: 10.3390/md17110609.

Long-Lasting Neuropsychological Effects of a Computerized Cognitive Training in Patients Affected by Early Stage Alzheimer's Disease: Are They Stable Over Time?

Cavallo M, Angilletta C.

J Appl Gerontol. 2019 Jul;38(7):1035-1044. doi: 10.1177/0733464817750276. Epub 2018 Jan 2.

Monotherapy Is Good Enough for Patients with Mild-to-Moderate Alzheimer's Disease: A Network Meta-analysis of 76 Randomized Controlled Trials

Tsoi KK, Chan JY, Chan FC, Hirai HW, Kwok TC, Wong SY.

Clin Pharmacol Ther. 2019 Jan;105(1):121-130. doi: 10.1002/cpt.1104. Epub 2018 Jun 19.

Drug development for Alzheimer's disease: review

Lao K, Ji N, Zhang X, Qiao W, Tang Z, Gou X.

J Drug Target. 2019 Feb;27(2):164-173. doi: 10.1080/1061186X.2018.1474361. Epub 2018 Jun 20.

An expanded theory of Alzheimer's caregiving

Lang SF, Fowers BJ.

Am Psychol. 2019 Feb-Mar;74(2):194-206. doi: 10.1037/amp0000323. Epub 2018 May 24.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias